Endoglin Expression as a Measure of Microvessel Density in Cervical Cancer

Brewer, Cheryl A.; Setterdahl, Jennifer J; LI, MIAO J.; Johnston, Jennifer; Mann, Jason R.; McAsey, Mary E.

doi:10.1097/00006250-200008000-00013

Cited by 23 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neoplastic, inflammatory, mesechymal, and hematopoietic cells were not stained with endoglin. These observations have been also reported previously for other solid malignancies [4,7,26,29,30,35,44]. In addition, in our samples, lymphatic vessels were generally negative for endoglin, as confirmed with double staining with the specific lymphatic endothelium marker D2-40.…”

Section: Discussionsupporting

confidence: 92%

“…An increasing amount of studies evaluating MVD with CD105, in various neoplasms, is being published [4,7,26,29,30,35,44]. So far, with no exceptions, in all of these studies, a significant association of high MVD with poor prognosis was observed, and investigators agree that assessment of microvessel counts with endoglin seems to be better than the use of any other pan-endothelial marker.…”

Section: Discussionmentioning

confidence: 99%

“…Intratumoral microvessel density (MVD) determined by antibodies against CD105 was correlated with decreased survival and increased tumor aggressiveness in a number of malignancies, such as breast cancer [7,18], cutaneous melanoma [29], colon cancer [26, 36,45], lung cancer [3,30,40], gynecological malignancies [4,35,38], and renal cancer [6,44]. It was suggested that CD105 might be the optimal antibody for microvessel's highlight to preclude disturbances caused by the low accuracy of the panendothelial markers (CD31, CD34, and von Willebrand factor) used so far [12][13][14]36].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma

2006

View full text Add to dashboard Cite

Endoglin (CD105) is a proliferation-associated protein abundantly expressed in angiogenic endothelial cells. Recent studies revealed that CD105 is intensively expressed in tumor vasculature, whereas intratumoral microvessel density (MVD) determined with the use of antibodies to CD105 has been found to be an important prognostic indicator for the outcome in a number of malignancies. In the current study, we investigated endoglin expression and evaluated MVD in 108 patients with head and neck squamous cell carcinoma. Endoglin was intensively expressed in intratumoral blood vessels, whilst lymphatics were rarely positive for CD105. High microvessel density was associated with a more aggressive tumor phenotype, including advanced clinical stage (p = 0.008) and the presence of lymph node metastasis at the time of diagnosis (p = 0.02). When microvessel counts were assessed for their prognostic values (high vs low MVD), there was a statistically significant difference in the overall survival among patients with tumors of the oral cavity and larynx (p < 0.001) and in the disease-free survival among patients with tumors of the lower lip (p = 0.01). The prognostic impact of microvessel density was not dependent on clinical stage or lymph node status. The results of the current study suggest that CD105 is a promising target for tumor imaging and prognosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma

2006

View full text Add to dashboard Cite

show abstract

“…Quantification of tumor microvessel density, as determined by immunohistochemical staining for CD105, is a significant indicator of poor prognosis in patients with selected solid neoplasias including NSCLC (Tanaka et al, 2001), cervical cancer (Brewer et al, 2000), prostate cancer with Gleason score 5-7 (Wikstrom et al, 2002) and breast carcinoma (Kumar et al, 1999;Dales et al, 2003). Moreover, a weaker intensity of staining for CD105 was observed in T1 compared to T2, T3 or T4 squamous cell carcinomas of the oral cavity (Schimming and Marme, 2002).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have defined the role of CD105 as a powerful marker to quantify intratumoral microvessel density (IMVD) in solid and hematopoietic tumors including breast (Kumar et al, 1999), prostate (Wikstrom et al, 2002), cervical (Brewer et al, 2000), colorectal (Akagi et al, 2002) and non-small cell lung cancer (NSCLC) (Tanaka et al, 2001), and in multiple myeloma (Pruneri et al, 2002) and hairy cell leukemia (Pruneri et al, 2003). Moreover, in NSCLC, increased levels of angiopoietin-2 (an antagonist of angiopoietin-1) significantly correlated with higher IMVD assessed by immunohistochemical staining against CD105.…”

Section: Functional Implications In Angiogenesis Vascular Developmenmentioning

confidence: 99%

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels

et al. 2003

View full text Add to dashboard Cite

Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -b receptor complex and is involved in vascular development and remodelling. Quantification of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to have prognostic significance in selected neoplasias. In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models.

show abstract

Endoglin (CD105) expression on microvessel endothelial cells in juvenile nasopharyngeal angiofibroma: Tissue microarray analysis and association with prognostic significance

Wang

Sun

et al. 2013

Head & Neck

View full text Add to dashboard Cite

show abstract

Endoglin Expression as a Measure of Microvessel Density in Cervical Cancer

Cited by 23 publications

References 14 publications

Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma

Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels

Endoglin (CD105) expression on microvessel endothelial cells in juvenile nasopharyngeal angiofibroma: Tissue microarray analysis and association with prognostic significance

Contact Info

Product

Resources

About